Douglas A Marchuk Selected Research

Central Nervous System Cavernous Hemangioma

5/2022	Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans.
1/2022	Propranolol as therapy for cerebral cavernous malformations: a cautionary note.
1/2021	Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models.
1/2021	Cerebral Cavernous Malformation: From Mechanism to Therapy.
1/2021	PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism.
10/2020	Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican.
1/2017	RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
1/2016	B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models.
1/2016	Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease.
3/2015	Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Douglas A Marchuk Research Topics

Disease

17	Central Nervous System Cavernous Hemangioma 05/2022 - 02/2002
11	Hemorrhage 05/2022 - 10/2004
7	Vascular Malformations 10/2021 - 02/2004
6	Hereditary Hemorrhagic Telangiectasia 01/2021 - 02/2004
5	Arteriovenous Malformations (Arteriovenous Malformation) 01/2021 - 02/2004
4	Ischemia 07/2017 - 12/2009
4	Cardiomyopathies (Cardiomyopathy) 01/2013 - 06/2005
4	Hereditary Spastic Paraplegia 05/2010 - 11/2002
3	Infarction (Infarctions) 01/2021 - 01/2013
3	Ischemic Stroke 01/2021 - 01/2016
2	Familial cerebral cavernous malformation 06/2022 - 01/2021
2	Cavernous Hemangioma (Cavernous Angioma) 01/2020 - 01/2019
2	Disease Progression 04/2013 - 01/2013
2	Hemangioma (Angioma) 07/2007 - 03/2002
2	Heart Failure 06/2005 - 12/2003
2	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 12/2003 - 04/2002
1	Necrosis 07/2017
1	Cerebral Infarction 01/2016
1	Myocardial Ischemia (Ischemic Heart Diseases) 03/2014
1	Sturge-Weber Syndrome (Sturge-Kalischer-Weber Syndrome) 05/2013
1	Port-Wine Stain (Nevus Flammeus) 05/2013
1	Central Nervous System Vascular Malformations (Dural Arteriovenous Fistula) 04/2013
1	Brain Injuries (Brain Injury) 01/2013
1	Stroke (Strokes) 01/2013
1	Atrophy 05/2012
1	Inflammation (Inflammations) 02/2012
1	Neurodegenerative Diseases (Neurodegenerative Disease) 05/2010
1	Heart Diseases (Heart Disease) 09/2009
1	Intermittent Claudication 03/2008
1	Pain (Aches) 03/2008
1	Chronic Limb-Threatening Ischemia 03/2008
1	Myocardial Infarction 01/2008
1	Friedreich Ataxia (Friedreich's Ataxia) 04/2006
1	Vascular Remodeling 03/2005
1	Neoplasms (Cancer) 03/2004
1	Mood Disorders (Mood Disorder) 03/2002

Drug/Important Bio-Agent (IBA)

9	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2002
6	Phosphotransferases (Kinase)IBA 01/2021 - 03/2002
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 02/2012
4	rho-Associated KinasesIBA 01/2020 - 02/2012
4	EndoglinIBA 02/2010 - 02/2004
4	CalsequestrinIBA 09/2009 - 04/2002
3	Propranolol (Inderal)FDA LinkGeneric 01/2022 - 01/2021
3	IronIBA 01/2020 - 01/2016
3	CytokinesIBA 01/2018 - 10/2004
3	SpastinIBA 05/2010 - 09/2004
3	Activin Receptors (Activin Receptor)IBA 12/2008 - 02/2004
2	MicroRNAs (MicroRNA)IBA 06/2022 - 01/2019
2	Adrenergic Receptors (Adrenergic Receptor)IBA 10/2021 - 01/2021
2	Neuroprotective AgentsIBA 01/2021 - 01/2016
2	Pharmaceutical PreparationsIBA 11/2020 - 01/2016
2	fasudil (AT 877)IBA 01/2017 - 02/2012
2	Messenger RNA (mRNA)IBA 01/2013 - 07/2011
2	IntegrinsIBA 01/2013 - 02/2002
2	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 01/2008 - 03/2002
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2004 - 03/2002
1	Sirolimus (Rapamycin)FDA Link 05/2022
1	CHR 8IBA 01/2021
1	Adrenergic Antagonists (Antiadrenergic Agents)IBA 01/2021
1	LipopolysaccharidesIBA 11/2020
1	Versicans (Versican)IBA 10/2020
1	Transcription Factors (Transcription Factor)IBA 10/2020
1	Interleukin-4 (Interleukin 4)IBA 01/2018
1	Green Fluorescent ProteinsIBA 07/2017
1	Simvastatin (Zocor)FDA LinkGeneric 01/2017
1	Interleukin-21 ReceptorsIBA 01/2016
1	Caspase 3 (Caspase-3)IBA 01/2016
1	Heme (Haem)IBA 01/2016
1	Epidermal Growth Factor (EGF)IBA 09/2015
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 09/2015
1	Troponin IIBA 03/2014
1	DNA (Deoxyribonucleic Acid)IBA 05/2013
1	NucleotidesIBA 05/2013
1	LuciferasesIBA 05/2013
1	AntibodiesIBA 05/2013
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2012
1	Ethylnitrosourea (N-Ethyl-N-nitrosourea)IBA 05/2009
1	rho GTP-Binding Proteins (rho GTP-Binding Protein)IBA 02/2009
1	Retinaldehyde (Retinal)IBA 07/2007
1	ApolipoproteinsIBA 05/2006
1	FrataxinIBA 04/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2006
1	Transforming Growth Factor-beta Type I ReceptorIBA 03/2005
1	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2005
1	Complementary DNA (cDNA)IBA 02/2004
1	PhosphotyrosineIBA 12/2003
1	KinesinsIBA 11/2002
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 03/2002
1	Androgen Receptors (Androgen Receptor)IBA 03/2002
1	Carrier Proteins (Binding Protein)IBA 02/2002
1	GTP Phosphohydrolases (GTPases)IBA 02/2002

Therapy/Procedure

4	Therapeutics 01/2022 - 04/2013
1	Aftercare (After-Treatment) 01/2020
1	Limb Salvage 12/2009
1	Surgical Amputation (Amputations) 03/2008